Lazard Asset Management LLC Gritstone Bio, Inc. Transaction History

Lazard Asset Management LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	BUY	$1.96 - $2.9 $53,823 - $79,636	27,461 New	27,461 $70,000
Q3 2023 Nov 14, 2023	BUY	$1.19 - $2.26 $320 - $607	269 Added 4.78%	5,900 $10,000
Q2 2023 Aug 14, 2023	BUY	$1.66 - $3.03 $247 - $451	149 Added 2.72%	5,631 $10,000
Q1 2023 May 15, 2023	BUY	$2.13 - $3.74 $2,432 - $4,271	1,142 Added 26.31%	5,482 $14,000
Q4 2022 Feb 14, 2023	BUY	$2.17 - $3.92 $9,417 - $17,012	4,340 New	4,340 $14,000
Q1 2022 May 13, 2022	SELL	$4.03 - $12.19 $5,017 - $15,176	-1,245 Closed	0 $0
Q4 2021 Feb 09, 2022	SELL	$8.76 - $13.71 $49,721 - $77,817	-5,676 Reduced 82.01%	1,245 $16,000
Q3 2021 Nov 15, 2021	SELL	$6.41 - $13.54 $3,698 - $7,812	-577 Reduced 7.7%	6,921 $74,000
Q2 2021 Aug 12, 2021	BUY	$8.13 - $10.2 $60,958 - $76,479	7,498 New	7,498 $68,000
Q4 2020 Feb 11, 2021	SELL	$2.57 - $4.22 $514 - $844	-200 Closed	0 $0
Q2 2020 Aug 13, 2020	BUY	$5.69 - $8.17 $1,138 - $1,634	200 New	200 $1,000

35.4M

395K

132K

Ticker GRTS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 73,006,896
Market Cap $2.19M
Description
Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing immunotherapies against multiple cancer types and infectious diseases. Its lead product candidate is GRANITE, a neoantigen-based immunotherapy for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder ...

Get notified when there are updates to the investment portfolio of Lazard Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Lazard Asset Management LLC with notifications on news.